BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9799343)

  • 1. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
    Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
    Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
    O'Byrne KJ; O'Hare N; Sweeney E; Freyne PJ; Cullen MJ
    Nucl Med Commun; 1996 Sep; 17(9):810-6. PubMed ID: 8895910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma.
    Berná L; Cabezas R; Mora J; Torres G; Estorch M; Carrió I
    J Endocrinol; 1995 Feb; 144(2):339-45. PubMed ID: 7706986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
    Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I
    Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
    Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
    Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
    Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
    J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
    Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
    Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
    Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
    Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma].
    Czepczyński R; Kosowicz J; Ziemnicka K; Mikołajczak R; Gryczyńska M; Sowiński J
    Endokrynol Pol; 2006; 57(4):431-5. PubMed ID: 17006849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.
    Krausz Y; Rosler A; Guttmann H; Ish-Shalom S; Shibley N; Chisin R; Glaser B
    Clin Nucl Med; 1999 Apr; 24(4):256-60. PubMed ID: 10466522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
    Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
    J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.
    Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O
    World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
    Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
    Rufini V; Salvatori M; Saletnich I; Valenza V; Maussier ML; Martino G; Corsello SM; Pantusa M; Casolo A; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Becker H; Becker W
    Eur J Nucl Med; 1997 Feb; 24(2):184-91. PubMed ID: 9021116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.